All Topics

Subscribe
Article
Big Agenda, Small Docket: Decoding The EEOC’s Surprisingly Muted FY 2026
The EEOC filed only 97 merit lawsuits in fiscal year 2026, marking another year of historically low litigation activity despite regaining its quorum and new leadership under Chair Andrea Lucas. While overall filing numbers remained subdued, the composition reveals a strategic shift toward religious discrimination claims, pregnancy-related litigation, and majority-group discrimination cases that align with the Trump Administration's enforcement priorities.
United States Employment
SS
Seyfarth Shaw LLP
Article
Celebrating California’s Water Professionals
California's water professionals work tirelessly to ensure safe and reliable water, wastewater, and recycled water services across the state, especially as the region faces a hotter, drier climate with extreme weather events. This recognition highlights the essential expertise and dedication these professionals bring to their communities while encouraging the next generation to consider rewarding careers in the water industry.
United States Energy
N
Nossaman LLP
Article
Structuring Deals Around Washington’s 2027 REET Shifts
While those upward bracket shifts may provide meaningful tax savings on higher-value properties, Washington’s Real Estate Excise Tax (“REET”) structure remains one of the most closely watched elements of transactional planning for commercial and residential property owners and developers. Because Washington applies a tiered, progressive REET rate system for real estate sales, alongside strict rules governing the transfer of controlling interests in entities that own real property, even minor statutory adjustments can drastically alter the economics of a transaction if deal timing or contract mechanics are mishandled.
United States Tax
BB
Beresford Booth
Article
When FDA Oversees Trials Overseas: Foreign Clinical Trial Considerations
The FDA's acceptance of foreign clinical trial data hinges on strict compliance with good clinical practice standards, population representativeness, and data integrity requirements that sponsors must carefully navigate. As the agency intensifies scrutiny of non-U.S. trial sites and emphasizes demographic diversity in study populations, pharmaceutical companies face mounting challenges in ensuring their international research programs meet evolving regulatory expectations.
United States Healthcare
FH
Foley Hoag LLP
See more